impact factor, citescore
logo
 

Full Papers

 

Short-term costs associated with non-medical switching in autoimmune conditions


1, 2, 3, 4, 5, 6

 

  1. Hospital for Special Surgery-Weill Cornell Medicine, New York, NY, USA. gibofskya@hss.edu
  2. AbbVie, North Chicago, IL, USA.
  3. Analysis Group, Inc, Boston, MA, USA.
  4. AbbVie, North Chicago, IL, USA.
  5. Analysis Group, Inc, New York, NY, USA.
  6. AbbVie, North Chicago, IL, USA.

CER11182
2019 Vol.37, N°1
PI 0097, PF 0105
Full Papers

Free to view
(click on article PDF icon to read the article)

PMID: 29998841 [PubMed]

Received: 16/02/2018
Accepted : 16/04/2018
In Press: 25/06/2018
Published: 18/01/2019

Abstract

OBJECTIVES:
To estimate short-term costs associated with non-medical switch (NMS) from originator biologics to biosimilars among stable patients with autoimmune conditions in rheumatology, gastroenterology, and dermatology from a US provider’s and third-party payer’s perspective.
METHODS:
An economic model was constructed to estimate switching costs related to physician time and healthcare resource utilisation (HRU) at the initial NMS visit and over 3 months. The proportion of patients with relevant conditions treated with originators and expected NMS rate, physician time, HRU, and payer reimbursement were derived from a physician survey. Switching costs were estimated for a practice of 1,000 patients with relevant conditions by therapeutic area and for an insurance plan with 1 million individuals by therapeutic area and all areas combined. Switching cost drivers were assessed with one-way sensitivity analyses.
RESULTS:
Physicians expected extra 6 minutes for the NMS visit and 22 minutes over 3 months; NMS rates of 14.4%, 15.5%, and 17.7%; and 11.3%, 16.2%, and 33.2% of time not reimbursed for gastroenterology, rheumatology, and dermatology, respectively. The total switching costs for payer’s were $771,460 (for n = 3,609 patients with an NMS rate of 16.6%), mostly due to follow-up visits and additional laboratory tests/procedures. In sensitivity analyses, the NMS rate was the main cost driver. Increasing the NMS rate to 25% and 50% increased payer’s total switching costs to $1.19 and $2.39 million, respectively.
CONCLUSIONS:
Originator-to-biosimilar NMS in stable patients with autoimmune conditions could result in considerable switching costs for both providers and payers.

Rheumatology Article

Rheumatology Addendum